PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “PANCREATIC NEOPLASMS”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3Linked to original sources
PubMed2001

[Prospective study to compare high-resolution computed tomography and magnetic resonance imaging in the detection of pancreatic neoplasms: use of intravenous and oral MR contrast media].

PURPOSE: To compare thin-section hydro-CT and MRI in the detection of pancreatic neoplasms. Evaluation of an oral, superparamagnetic contrast agent (OMP) for pancreatic MRI. MATERIAL AND METHODS: 45 patients with suspected pancreatic neoplasms were examined with consecutive thin-section helical CT (Hydro-CT, 3/6/3, 130 ml Ultravist, Schering) and MRI (1.0 T, breath-holding, T1w-GRE, T1w-GRE fat-sat, T2w-TSE). The MRI protocol included precontrast studies, studies after oral administration of OMP (Abdoscan, Nycomed Amersham) and studies after administration of OMP and Gadodiamide i.v. (Omniscan, Nycomed Amersham). All images were assessed by two independent radiologists in a blinded fashion. Radiologic diagnosis was correlated with histology or clinical follow-up (> or = 3 month). RESULTS: 39 patients could be included in analysis. In 13 cases a pancreatic neoplasm was proven by histology. Thin-section hydro-CT and MRI showed no statistically significant differences for the detection of pancreatic neoplasia. The sensitivity of helical hydro-CT was superior compared to MRI (88.5% vs. 65.44/73.1%/76.9%). The specificity of MRI was superior compared to helical hydro-CT (86.5% vs. 94.2%/90.4%/88.5%). CONCLUSION: Thin-section hydro-CT and MRI show similar results for the detection of pancreatic neoplasms. Compared to thin-section helical CT, MRI still has the drawbacks of much more time consumption and, still, lower spatial resolution. The use of an oral, superparamagnetic contrast agent added no advantage for pancreatic MRI.

Administration, Oral↗
PubMed1982

Imaging the pancreatic neoplasm.

The radiologic approach to the pancreatic mass is discussed. The efficacy of the various diagnostic methods is also discussed. Cross-sectional imaging techniques have greatly improved the accuracy of diagnosis of pancreatic lesions and are less invasive than either angiography or ERCP. Computed tomography is more reliable than sonography and should be the initial diagnostic procedure in any patient who is suspected of having a pancreatic neoplasm.

Angiography↗
PubMed2002

Expression of maspin in pancreatic neoplasms: application of maspin immunohistochemistry to the differential diagnosis.

Maspin is a unique member of the serpin family, which inhibits tumor invasion and metastasis of the human breast and prostate cancers. Immunohistochemical evaluation of the maspin expression in pancreatic neoplasms has never been performed. The authors examined the expression of maspin in various pancreatic neoplasms to investigate its usefulness as an adjunct diagnostic marker. Formalin-fixed, paraffin-embedded tissue sections from 107 pancreatic neoplasms were immunostained with anti-maspin antibody using an EnVision+ System. Maspin was expressed in all ductal adenocarcinomas, of which 78.9% (30/38) were high expressors and 21.1% (8/38) were low expressors. All 13 intraductal papillary mucinous tumors and 11 of the 13 mucinous cystic tumors reacted to maspin with stronger expressions in carcinomatous lesions. In contrast, acinar cell carcinoma, pancreatic endocrine tumors, solid-pseudopapillary tumors, and serous cystadenomas demonstrated no maspin expression. In addition, nonneoplastic pancreatic parenchyma and chronic pancreatitis lacked expression. The current study suggests that maspin may be of importance in the pathobiology of pancreatic neoplasms with epithelial origin, especially pancreatic tumors that are composed of mucin-producing cells. It may be useful in separating ductal adenocarcinoma from acinar cell carcinoma, pancreatic endocrine tumor, solid-pseudopapillary tumor, and chronic pancreatitis, especially in needle biopsy specimens.

Diagnosis, Differential↗
PubMed2001

Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors.

BACKGROUND: Cyclooxygenase-2 (COX-2) is thought to be linked to carcinogenesis; however, very little is known about its expression in pancreatic neoplasms. The authors studied the expression of COX-2 in human pancreatic neoplasms and investigated the effect of COX inhibitors on the growth of human pancreatic carcinoma cells. METHODS: Expression of COX-2 protein was immunohistochemically examined in 42 human pancreatic duct cell carcinomas (PDCs) and in 29 intraductal papillary mucinous tumors (IPMTs [adenomas, 19; carcinomas, 10]) of the pancreas that were resected surgically at the National Cancer Center Hospital in Tokyo. The growth of four human pancreatic carcinoma cell lines also was evaluated in the presence of COX inhibitors. RESULTS: Marked COX-2 expression was observed in 57% (24 of 42) of PDCs, in 58% (11 of 19) of adenomas, and in 70% (7 of 10) of adenocarcinomas of IPMTs. However, there was no correlation between COX-2 expression and clinicopathologic indices of the patients. All four pancreatic cancer cell lines expressed COX-2 protein weakly or strongly, and the inhibitory effect of aspirin on cell growth was correlated with the expression of COX-2. CONCLUSIONS: COX-2 was expressed in adenomas of IPMTs as well as in carcinomas and might have played a role in the development of pancreatic tumors. In this study, COX inhibitors, as nonsteroidal anti-inflammatory drugs, were shown to be possible preventive agents against pancreatic neoplasms.

Adenocarcinoma, Mucinous↗
PubMed2003

Pancreatic neoplasms.

PURPOSE OF REVIEW: This review describes significant basic science and clinical advances in the field of pancreatic neoplasms. RECENT FINDINGS: Some of the genetic and molecular bases for the aggressive behavior of pancreatic cancer have been uncovered, and new targets for therapy have been identified. Various techniques for diagnosis and staging of this disease-endoscopic ultrasound, laparoscopy-continue to undergo evaluation. Surgical results show slightly improved long-term survival, and perioperative mortality rates remain low. The concept that locally invasive pancreatic cancer can be effectively downstaged and later resected has been called into question. Regional chemotherapy has shown promise, especially when combined with immunotherapy. Intraductal papillary mucinous tumors continue to be commonly encountered and their development and clinical course intensely studied. Acinar cell carcinomas are rare pancreatic neoplasms associated with postresection survival longer than ductal adenocarcinoma but shorter than endocrine carcinoma. Neoplasms metastatic to the pancreas can be resected safely and with improved survival compared with nonsurgical therapies. SUMMARY: The treatment of pancreatic neoplasms remains a major challenge for physicians and surgeons. Future progress requires sound scientific inquiry and continued clinical diligence.

Journal Article↗
PubMed1983

Sonographic pitfalls in the diagnosis of pancreatic neoplasms.

False sonographic diagnoses were analyzed in a series of 51 patients with pancreatic neoplasms. Sonography indicated 40 of these, leaving 11 cases of false-negatives. In addition, 11 cases were falsely suggested (false-positives). Sonography overlooked 15.5% of the cases when definite observer errors were excluded. Of the 22 falsely diagnosed cases, 12 had obstructive jaundice, which may have affected the diagnosis. Large tumors were detected but their origin was difficult to determine. Although sonography may be reliable in suggesting a pancreatic neoplasm, other differential diagnoses have to be taken into account as well.

False Positive Reactions↗
PubMed2004

Pancreatic neoplasms.

PURPOSE OF REVIEW: This review includes a summary of articles that have affected the study and treatment of pancreatic neoplasms over the past year. RECENT FINDINGS: Over the past year, there have been several reports of new animal models of pancreatic cancer that recapitulate the human disease and hold promise for preclinical studies. The hope of proteomic and DNA technologies for detecting pancreatic cancer and new genes involved in the biology of this disease are described. New studies examining neoadjuvant and adjuvant treatment of pancreatic cancer show some promise. The surgical treatment and palliation of pancreatic cancer continues to advance. Experiences of the treatment of intraductal pancreatic mucinous neoplasms shed some light on the management of this entity. Two large series of cystic neoplasms point to the evolving management of these often asymptomatic lesions. SUMMARY: The treatment of pancreatic neoplasm continues to change and improve as more is learned about these diseases. A renewed clinical and scientific focus on this organ will certainly shape the management of pancreatic neoplasm and holds the promise of improved outcomes.

Journal Article↗
PubMed2001

Radiologic features of cystic, endocrine and other pancreatic neoplasms.

This article presents imaging features of cystic, endocrine and other pancreatic neoplasms. Microcystic adenoma which is composed of small cysts (<2 cm), its macrocystic subgroup contains solitary cyst. Multiple cysts larger than 2 cm are associated with mucinous cystic neoplasm. Swiss cheese appearence with central calcification is characteristic for microcystic adenomas. Septal and mural enhancement as well as larger size (>2 cm) are accounted for mucinous cystic neoplasms, its variant along pancreatic duct is ductectatic mucinous cystic neolasm. Endocrine tumors of pancreas are hypervascular and can be depicted on early dynamic enhanced crosssectional imaging modalities or on angiography when they are <1 cm. Pancreatic metastases and lymphomas are rare neoplasms which should also be included in differential diagnosis for pancreatic masses.

Cystadenocarcinoma↗
PubMed1975

Pancreatic neoplasms in an animal model: morphological, biological, and comparative studies.

After a short latency (15 weeks), a 100% incidence of pancreatic neoplasms was induced in Syrian golden hamsters, following the administration of 2,2'-dihydroxy-di-n-propylnitrosamine (DHPN). Data extracted from reports of human pancreatic neoplasms were compared with findings relative to the induced neoplasms. The latter resembled human pancreatic tumors, in both biological and morphological aspects.

Adenocarcinoma↗
PubMed1997

Usefulness of simple endoscopic aspiration cytology of pancreatic juice for diagnosis of early pancreatic neoplasm. A prospective study.

For detection of early cancer of the pancreas, endoscopic aspiration cytology of pancreatic juice without endoscopic retrograde pancreatography was performed in 64 consecutive outpatients who had symptoms or findings that suggested pancreatic disease. Patients with positive or suspicious cytologic results or abnormal US findings were admitted and underwent detailed examinations. Positive and suspicious cytologic results were obtained in 2 and 10 patients, respectively. Of those with positive and suspicious cytologic results, two, and one patient, respectively, were ultimately found to have pancreatic neoplasms. Of these three resected specimens, one was in situ carcinoma and two presented marked atypia. All patients were alive with no evidence of recurrence. No further cases of pancreatic neoplasm were found. Complications from the procedure did not develop in any patient. This technique is useful in the diagnosis of early neoplasms of the pancreas, because it is simple and safe to perform for outpatients.

Aged↗
PubMed2004

Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms.

Pancreatic endocrine neoplasms are neoplastic proliferations of islet cells or islet cell precursors and are capable of secreting a variety of synthetic products, including insulin, glucagon, gastrin, and vasoactive intestinal peptide. The biological behavior of pancreatic endocrine neoplasms is often unpredictable, and there are few reliable histopathologic criteria reliably correlating with metastatic ability. We have used the Affymetrix U133 GeneChip set (HG_U133 A and B; Affymetrix; Santa Clara, CA) representing approximately 33,000 characterized transcripts to examine global gene expression profiles from well-differentiated nonmetastatic (n=5) and metastatic (n=7) pancreatic endocrine neoplasms to determine molecular markers that predict disease progression. Microarray hybridization data were normalized using the GeneLogic GeneExpress Software System to identify differentially up- and down-regulated genes in metastatic versus nonmetastatic pancreatic endocrine neoplasms. Using a 3-fold change in gene expression as a threshold, we have identified 65 overexpressed and 57 underexpressed genes in metastatic pancreatic endocrine neoplasms as compared with nonmetastatic pancreatic endocrine neoplasms. Several classes of genes, including growth factors and growth factor-related molecules (IGFBP1, IGFBP3, and MET), developmental factors (TBX3 and MEIS2), cytoskeletal factors (beta 1 tubulin and ACTN2), cholesterol homeostasis mediators (LRP5, SLC27A2, and RXRG), intracellular signaling pathway mediators (DYRK1A, PKIB, and AK2), methyltransferases (MGMT and GAMT), and DNA repair and regulatory molecules (CHEK1 and ZNF198), were identified as differentially over- or underexpressed via this method. Immunohistochemical validation of microarray data were performed for two overexpressed genes, namely, the met proto-oncogene (MET) and insulin-like growth factor binding protein 3 (IGFBP3) with tissue microarrays of nonmetastatic (n=24) and metastatic (n=15) pancreatic endocrine neoplasms. Increased expression of IGFBP3 was confirmed in metastatic versus nonmetastatic pancreatic endocrine neoplasms (12 of 15, 80% versus 10 of 24, 42%), as well as in lymph node (6 of 7, 86%) and liver (9 of 9, 100%) metastases. Similarly, overexpression of MET was confirmed in metastatic versus nonmetastatic pancreatic endocrine neoplasms (5 of 15, 33% versus 4 of 24, 17%), as well as in lymph node metastases (4 of 7, 57%) and liver metastases (5 of 9, 56%). The majority of genes that demonstrated altered expression has not been previously identified as differentially expressed in metastatic pancreatic endocrine neoplasm lesions and may therefore represent newly identified molecules in the progression of these lesions.

Aged↗
PubMed1993

Computed tomographic and cytologic assessment of cystic pancreatic neoplasms: a difficult preoperative diagnosis.

The computed tomography (CT) findings or cytologic results, or both, for 21 patients with cystic pancreatic neoplasm (4 with microcystic cystadenoma, 6 with macrocystic mucinous cystadenoma, 10 with macrocystic mucinous cystadenocarcinoma and 1 with a papillary cystic neoplasm) were reviewed. CT scans for 14 of the patients were reviewed by two gastrointestinal radiologists who were blinded with respect to the patients' identities and the diagnoses. The radiologists used previously published criteria for distinguishing between microcystic and macrocystic neoplasms. Of the four cases of microcystic cystadenoma, two were correctly diagnosed by one radiologist, and one was correctly diagnosed by the other. Three and four cases respectively of five cases of macrocystic cystadenoma were correctly identified, as were three and five of five cases of macrocystic cystadenocarcinoma. Cytologic evaluation of samples from fine-needle aspiration biopsy had been performed for 15 of the patients, and these records were reviewed. One of three cases of microcystic cystadenoma, two of four cases of macrocystic cystadenoma, five of seven cases of macrocystic cystadenocarcinoma and the papillary cystic neoplasm were correctly diagnosed on the basis of the cytologic findings. The combination of CT and cytologic assessment is helpful in distinguishing different types of cystic pancreatic neoplasms, but there is significant overlap among the clinical and radiographic features of these lesions, and therefore operative assessment is often necessary.

Adult↗
PubMed2005

Pancreatic neoplasms.

Patients who present with signs and symptoms suggesting a pancreatic neoplasm typically undergo initial imaging with transabdominal ultrasound or CT. When a pancreatic mass or fullness is identified, it may represent an inflammatory mass, benign process, or malignancy. Endoscopic ultrasound (EUS) is performed commonly to further characterize the lesion, obtain a tissue diagnosis, and for staging. This article reviews the role of EUS for the diagnosis and staging of pancreatic tumors.

Adenocarcinoma↗
PubMed2006

Magnetic resonance imaging in the detection of pancreatitis and pancreatic neoplasms.

This article presents current magnetic resonance imaging techniques for the diagnosis of acute and chronic pancreatitis and pancreatic neoplasms. It emphasises the need for a comprehensive protocol combining imaging sequences of the pancreatic parenchyma with magnetic resonance angiography and secretin-enhanced magnetic resonance cholangiopancreatography in order to evaluate the full range of pancreatic inflammatory and neoplastic conditions. Imaging characteristics that may indicate a specific diagnosis are discussed.

Humans↗
PubMed2000

Cystic pancreatic neoplasms: computed tomography and magnetic resonance imaging findings.

Cystic pancreatic neoplasms include serous cystadenomas (SCA), mucin-producing cystic tumors, cystic islet-cell tumors, and cystic solid and papillary epithelial neoplasms. Imaging techniques are of great value in the demonstration and differential diagnosis of these tumors. In this article we present the computed tomography (CT) and magnetic resonance imaging (MRI) findings of the aforementioned cystic neoplasms. Although the radiological features are in many cases informative, a significant overlap does exist; fine-needle aspiration biopsy and cytology or excisional biopsy and histological examination are necessary to determine a definitive diagnosis.

Adenoma, Islet Cell↗